Thursday , May 19 2022

Brokerage Proposals Iterum Therapeutics PLC (ITRM) to publish – $ 2.55 EPS


Vall Stretch Analysts predict that Iterum Therapeutics PLC (NASDAQ: ITRM) will announce earnings of $ 2.55 per share for the current quarter, reports Zacks. Zero analysts gave estimates for earnings Iterum Therapeutics. On Wednesday, February 13, the company will announce the results of the next earnings.

On average, analysts expect Iterum Therapeutics to report a total $ 10.82 per share for the current fiscal year, with EPS estimates ranging from ($ 11.04) to ($ 10.60). For the next financial year, analysts predict that the business will report earnings of ($ 6.38 per share), and EPS estimates range from $ 7.00 to $ 5.76. EPS's Zacks Investment Surveys are the average averages based on research by research firms dealing with sales monitored by Iterum Therapeutics.

Iterum Therapy (Nasdaq: ITRM) last published earnings results on Wednesday, November 14th. The company posted $ 1.24 per share per share (EPS) for a quarter, which decided to estimate Thomson Reuters' consensus of $ 1.97 for $ 0.73. The firm had $ 0.25 million revenue per quarter.

The ITRM was the subject of several research reports. Needham & Compani LLC set a target price of $ 20.00 to Iterum Therapeutics and gave a "BUY" rating to the survey on Wednesday. Gabelli repeated the purchase of a rating for Iterum Therapeutics in a survey on Monday, October 22. Finally, Zacks Investment Research raised Iterum Therapeutics from the rating "sell" to the "hold" rating in the research report on Friday. One research analyst rated the ratings with a rating for maintenance and five gave the rating a rating on the stock of the company. The company has an average "purchase" rating and a target price of $ 20.75.

In related news, Mark Chin, in a transaction on Tuesday, October 30th, bought 58,000 shares of Iterum Therapeutics. The shares were bought at an average price of $ 6.10 per share, with a total value of $ 353,800.00. The transaction was detected in a document submitted to the DIK, which is available through this link. In the last 90 days, insiders acquired a total of 60,000 shares of the company in the amount of $ 374,020.

A number of hedge funds recently bought and sold ITRM shares. Hound Partners LLC bought a new stake in Iterum Therapeutics in the 3rd quarter worth about $ 129,000. Glen Harbor Capital Management LLC bought a new position in Iterum Therapeutics in the second quarter, valued at around $ 318,000. Dean Capital Investments Management LLC bought a new position in Iterum Therapeutics in the second quarter of $ 406,000. Tiers Asset Management LLC bought a new position in the Iterum Therapeutics campaign in the second quarter, worth around $ 437,000. In the end, Flinton Capital Management LLC bought a new position in Iterum Therapeutics in the second quarter of about $ 556,000. 47.63% of shares are currently owned by institutional investors.

ITRM traded on Friday at $ 0.11 during a trading day, reaching $ 5.81. 11,530 shares of shares were exchanged, compared with an average volume of 12,187. Iterum Therapeutics has a 1 year low of $ 5.31 and a 1 year high of $ 13.00. The company has a debt ratio of 0.15, a current ratio of 14.05 and a quick ratio of 11.53.

Company Profile Iterum Therapeutics

Iterum Therapeutics plc, a pharmaceutical company in the clinical stage, is committed to the development of anti-infective agents for pathogens resistant to drugs in Ireland and the United States. The company develops a sulopenem, a peneal antiinfective compound with oral and IV formulations found in clinical trials of the third phase for the treatment of adults in non-complicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured article: What factors trigger inflation growth?

Get a free copy of the Zacks report on Iterum Therapeutics (ITRM)

For more information on Zacks Investment Research research visit

History of Earnings and Assessment of Iterum Therapy (Nasdaq: ITRM)

You get news and ratings for Iterum Therapeutics Daili – Enter your email address below to get a concise daily review of the latest news and analysts for Iterum Therapeutics and related companies with the FREE Daily newsletter.

Source link